Tech Company Financing Transactions
Kineta Funding Round
On 2/8/2013, Kineta landed financing from RLB Holdings.
Transaction Overview
Company Name
Announced On
2/8/2013
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
RLB Holdings (Lydia Bartoszek)
Proceeds Purpose
The two drug programs funded by the investment partnership are ShK-186, a novel immune-sparing targeted therapeutic focused on autoimmune diseases and rOAS, a novel pan-viral therapeutic aimed at an array of malicious viruses for which there are few effective therapies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
219 Terry Ave. N 300
Seattle, WA 98109
USA
Seattle, WA 98109
USA
Phone
Website
Email Address
Overview
Through Kineta, our pioneering team is dedicated to further study of innate immunity with an aggressive strategy to develop early stage programs for powerful new antiviral and immune modulating drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shawn Iadonato
Controller
Chanya Swartz
President
Craig Philips
Vice President
Thierry Guillaudeux
VP - Bus. Development
Jacques Bouchy
VP - General Counsel
Pauline Kenny
VP - Human Resources
Molly Dorr
VP - R & D
Eric Tarcha
Browse more venture capital transactions:
Prev: 2/8/2013: AlchemyAPI venture capital transaction
Next: 2/8/2013: Proton Digital Systems venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document tech company VC transactions. VC investment data records on this site are derived from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs